Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 2
1954 4
1956 1
1962 1
1963 1
1964 1
1966 4
1967 2
1968 5
1969 2
1970 6
1971 3
1972 3
1973 2
1974 4
1975 2
1976 3
1977 1
1978 5
1979 2
1980 11
1981 9
1982 9
1983 9
1984 10
1985 9
1986 22
1987 12
1988 23
1989 17
1990 13
1991 16
1992 21
1993 14
1994 25
1995 18
1996 24
1997 16
1998 22
1999 21
2000 22
2001 15
2002 20
2003 17
2004 14
2005 14
2006 25
2007 19
2008 8
2009 19
2010 30
2011 19
2012 34
2013 23
2014 25
2015 22
2016 34
2017 30
2018 27
2019 20
2020 39
2021 55
2022 54
2023 58
2024 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

964 results

Results by year

Filters applied: . Clear all
Page 1
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gómez-Reino JJ. Curtis JR, et al. Among authors: yamaoka k. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5. Ann Rheum Dis. 2023. PMID: 36600185 Free PMC article. Clinical Trial.
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Fleischmann R, et al. Among authors: yamaoka k. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12. Ann Rheum Dis. 2023. PMID: 37308218 Free PMC article. Clinical Trial.
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S, Kawaoka T, Yamasaki S, Johira Y, Kosaka M, Shirane Y, Miura R, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Miki D, Tsuge M, Teraoka Y, Kouno H, Takaki S, Mori N, Tsuji K, Oka S. Yano S, et al. Among authors: yamaoka k. Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406. Cancers (Basel). 2023. PMID: 38001666 Free PMC article.
The Janus kinases (Jaks).
Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. Yamaoka K, et al. Genome Biol. 2004;5(12):253. doi: 10.1186/gb-2004-5-12-253. Epub 2004 Nov 30. Genome Biol. 2004. PMID: 15575979 Free PMC article. Review.
Involvement of mast cells in systemic sclerosis.
Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Saito K, Tanaka Y. Yukawa S, et al. Among authors: yamaoka k. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(2):81-6. doi: 10.2177/jsci.33.81. Nihon Rinsho Meneki Gakkai Kaishi. 2010. PMID: 20453443 Free article. Review.
Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D.
Kato S, Kim MS, Yamaoka K, Fujiki R. Kato S, et al. Among authors: yamaoka k. Curr Opin Nephrol Hypertens. 2007 Jul;16(4):297-304. doi: 10.1097/MNH.0b013e3281c55f16. Curr Opin Nephrol Hypertens. 2007. PMID: 17565270 Review.
964 results